News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phenomix Corporation Announces Positive Results from a Phase 3 Study of Dutogliptin in Type 2 Diabetes Mellitus



4/20/2010 6:21:02 AM

SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

Read at Business Wire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES